Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:investigational_drug
gptkb:small_molecule |
| gptkbp:alternativeName |
Lisaftoclax
|
| gptkbp:clinicalTrialPhase |
gptkb:acute_myeloid_leukemia
chronic lymphocytic leukemia Phase 1 hematologic malignancies |
| gptkbp:developedBy |
gptkb:Ascentage_Pharma
|
| gptkbp:intendedUse |
gptkb:cancer
|
| gptkbp:mechanismOfAction |
induces apoptosis in cancer cells
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
gptkb:Bcl-2_protein
|
| gptkbp:bfsParent |
gptkb:Ascentage_Pharma
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
APG-2575 (Bcl-2 inhibitor)
|